Free tool
FAERS Monitor: Children'S Zyrtec Hives
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022155 or its brand name (Children'S Zyrtec Hives, Cetirizine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
33,446
Serious
24,449
73% of reports
Hospitalization
9,723
Death reported
5,134
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective9,681
- pain8,992
- fatigue8,987
- alopecia7,542
- rheumatoid arthritis7,475
- abdominal discomfort7,468
- systemic lupus erythematosus7,162
- pemphigus7,032
- off label use6,978
- rash6,766
- glossodynia6,535
- swelling6,096
- hypersensitivity5,829
- hand deformity5,687
- infusion related reaction5,618
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 19 |
| 2005 | 60 |
| 2006 | 20 |
| 2007 | 66 |
| 2008 | 170 |
| 2009 | 172 |
| 2010 | 629 |
| 2011 | 143 |
| 2012 | 164 |
| 2013 | 211 |
| 2014 | 242 |
| 2015 | 493 |
| 2016 | 1,002 |
| 2017 | 1,068 |
| 2018 | 1,152 |
| 2019 | 1,646 |
| 2020 | 2,243 |
| 2021 | 4,490 |
| 2022 | 4,566 |
| 2023 | 3,548 |
| 2024 | 4,387 |
| 2025 | 4,158 |
| 2026 | 2,797 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,020,713 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pemphigusSignal | 7,032 | 806.2 | 779.5 | 2,478,466 |
| hand deformitySignal | 5,687 | 480.2 | 464.7 | 1,542,370 |
| glossodyniaSignal | 6,535 | 258.8 | 251.9 | 1,189,662 |
| systemic lupus erythematosusSignal | 7,162 | 158.7 | 155.0 | 897,367 |
| infusion related reactionSignal | 5,618 | 58.1 | 56.7 | 289,619 |
| rheumatoid arthritisSignal | 7,475 | 44.2 | 43.3 | 296,765 |
| swellingSignal | 6,096 | 43.7 | 42.7 | 239,061 |
| abdominal discomfortSignal | 7,468 | 29.3 | 28.7 | 196,253 |
| alopeciaSignal | 7,542 | 25.1 | 24.6 | 169,199 |
| hypersensitivitySignal | 5,829 | 20.4 | 19.9 | 104,817 |
| rashSignal | 6,766 | 9.9 | 9.7 | 54,408 |
| painSignal | 8,992 | 9.3 | 9.2 | 67,847 |
| fatigueSignal | 8,987 | 7.3 | 7.2 | 50,439 |
| off label useSignal | 6,978 | 5.0 | 4.9 | 23,413 |
| drug ineffectiveSignal | 9,681 | 4.6 | 4.6 | 29,332 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.